{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:56:47Z","timestamp":1781719007251,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["12\/254"],"award-info":[{"award-number":["12\/254"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["18\/323"],"award-info":[{"award-number":["18\/323"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001505","name":"Health Research Council of New Zealand","doi-asserted-by":"publisher","award":["12\/788"],"award-info":[{"award-number":["12\/788"]}],"id":[{"id":"10.13039\/501100001505","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001511","name":"Auckland Medical Research Foundation","doi-asserted-by":"publisher","award":["1110014"],"award-info":[{"award-number":["1110014"]}],"id":[{"id":"10.13039\/501100001511","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006346","name":"Faculty of Medical and Health Sciences, University of Auckland","doi-asserted-by":"publisher","award":["Sir Owen Glenn Postdoctoral Clinical Research Fellowship"],"award-info":[{"award-number":["Sir Owen Glenn Postdoctoral Clinical Research Fellowship"]}],"id":[{"id":"10.13039\/501100006346","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001537","name":"University of Auckland","doi-asserted-by":"publisher","award":["Doctoral Scholarship"],"award-info":[{"award-number":["Doctoral Scholarship"]}],"id":[{"id":"10.13039\/501100001537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001537","name":"University of Auckland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s13318-026-01002-4","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T17:14:59Z","timestamp":1777569299000},"page":"401-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating Oxaliplatin Exposure in Adults with Advanced Colorectal Cancer: Development and Validation of Methods with Enhanced Bioanalytical Specificity and Clinical Applicability"],"prefix":"10.1007","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7228-7010","authenticated-orcid":false,"given":"John","family":"Ho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1016-3113","authenticated-orcid":false,"given":"Catherine","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7329-5503","authenticated-orcid":false,"given":"Mark James","family":"McKeage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"1","key":"1002_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1517\/14656566.2012.643870","volume":"13","author":"A Stein","year":"2012","unstructured":"Stein A, Arnold D. Oxaliplatin: a review of approved uses. Expert Opin Pharmacother. 2012;13(1):125\u201337. https:\/\/doi.org\/10.1517\/14656566.2012.643870.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"1002_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd1691","volume":"4","author":"D Wang","year":"2005","unstructured":"Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307\u201320. https:\/\/doi.org\/10.1038\/nrd1691 (Epub 2005\/03\/25).","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1002_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bcp.2008.04.007","volume":"76","author":"P Noordhuis","year":"2008","unstructured":"Noordhuis P, Laan AC, van de Born K, Losekoot N, Kathmann I, Peters GJ. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines. Biochem Pharmacol. 2008;76(1):53\u201361. https:\/\/doi.org\/10.1016\/j.bcp.2008.04.007.","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"1002_CR4","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0006-2952(97)81490-6","volume":"52","author":"O Rixe","year":"1996","unstructured":"Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, et\u00a0al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute\u2019s Anticancer Drug Screen panel. Biochem Pharmacol. 1996;52(12):1855\u201365. https:\/\/doi.org\/10.1016\/S0006-2952(97)81490-6.","journal-title":"Biochem Pharmacol"},{"issue":"36","key":"1002_CR5","doi-asserted-by":"publisher","first-page":"5910","DOI":"10.1200\/jco.2008.16.7759","volume":"26","author":"HT Arkenau","year":"2008","unstructured":"Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, et\u00a0al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil\/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol. 2008;26(36):5910\u20137. https:\/\/doi.org\/10.1200\/jco.2008.16.7759.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1002_CR6","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0090-9556(24)15087-8","volume":"28","author":"P Allain","year":"2000","unstructured":"Allain P, Heudi O, Cailleux A, Le Bouil A, Larra F, Boisdron-Celle M, et\u00a0al. Early biotransformations of oxaliplatin after its intravenous administration to cancer patients. Drug Metab Dispos. 2000;28(11):1379\u201384.","journal-title":"Drug Metab Dispos"},{"issue":"24","key":"1002_CR7","first-page":"5970","volume":"53","author":"L Pendyala","year":"1993","unstructured":"Pendyala L, Creaven PJ. In-vitro cytotoxicity, protein-binding, red-blood-cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993;53(24):5970\u20136.","journal-title":"Cancer Res"},{"issue":"16","key":"1002_CR8","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.1158\/1078-0432.ccr-07-0475","volume":"13","author":"CH Takimoto","year":"2007","unstructured":"Takimoto CH, Graham MA, Lockwood G, Ng CM, Goetz A, Greenslade D, et\u00a0al. Oxaliplatin pharmacokinetics and pharmacodynamics in adult cancer patients with impaired renal function. Clin Cancer Res. 2007;13(16):4832\u20139. https:\/\/doi.org\/10.1158\/1078-0432.ccr-07-0475.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1002_CR9","first-page":"1205","volume":"6","author":"MA Graham","year":"2000","unstructured":"Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6(4):1205\u201318.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1002_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1385\/MO:19:4:261","volume":"19","author":"H Ehrsson","year":"2002","unstructured":"Ehrsson H, Wallin I, Yachnin J. Pharmacokinetics of oxaliplatin in humans. Med Oncol. 2002;19(4):261\u20135. https:\/\/doi.org\/10.1385\/MO:19:4:261.","journal-title":"Med Oncol"},{"issue":"1","key":"1002_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/1471-2407-13-495","volume":"13","author":"C Han","year":"2013","unstructured":"Han C, Khwaounjoo P, Kilfoyle D, Hill A, McKeage M. Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients. BMC Cancer. 2013;13(1):495. https:\/\/doi.org\/10.1186\/1471-2407-13-495.","journal-title":"BMC Cancer"},{"issue":"4","key":"1002_CR12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1200\/JCO.1992.10.4.520","volume":"10","author":"DI Jodrell","year":"1992","unstructured":"Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, et\u00a0al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10(4):520\u20138. https:\/\/doi.org\/10.1200\/JCO.1992.10.4.520.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1002_CR13","first-page":"5432","volume":"44","author":"MJ Egorin","year":"1984","unstructured":"Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, Thompson BW, et\u00a0al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res. 1984;44(11):5432\u20138.","journal-title":"Cancer Res"},{"issue":"9","key":"1002_CR14","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1016\/S0959-8049(99)00029-5","volume":"35","author":"JP Sculier","year":"1999","unstructured":"Sculier JP, Paesmans M, Thiriaux J, Lecomte J, Bureau G, Giner V, et\u00a0al. A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer. Eur J Cancer. 1999;35(9):1314\u20139. https:\/\/doi.org\/10.1016\/S0959-8049(99)00029-5.","journal-title":"Eur J Cancer"},{"issue":"3","key":"1002_CR15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00280-014-2525-6","volume":"74","author":"QC du Rieu","year":"2014","unstructured":"du Rieu QC, White-Koning M, Picaud L, Lochon I, Marsili S, Gladieff L, et\u00a0al. Population pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive surgery: correlation between oxaliplatin exposure and thrombocytopenia. Cancer Chemother Pharmacol. 2014;74(3):571\u201382. https:\/\/doi.org\/10.1007\/s00280-014-2525-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"7","key":"1002_CR16","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1200\/jco.1997.15.7.2691","volume":"15","author":"MJ McKeage","year":"1997","unstructured":"McKeage MJ, Raynaud F, Ward J, Berry C, Odell D, Kelland LR, et\u00a0al. Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol. 1997;15(7):2691\u2013700. https:\/\/doi.org\/10.1200\/jco.1997.15.7.2691.","journal-title":"J Clin Oncol"},{"key":"1002_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/B978-0-12-369521-5.00010-5","volume-title":"Pharmacology","author":"JP Byers","year":"2009","unstructured":"Byers JP, Sarver JG. Chapter 10\u2014Pharmacokinetic modeling. In: Hacker M, Messer W, Bachmann K, editors. Pharmacology. San Diego: Academic; 2009. p. 201\u201377."},{"issue":"11","key":"1002_CR18","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1200\/jco.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA, O\u2019Reilly S, Burnell M, Boxall FE, et\u00a0al. Carboplatin dosage\u2014Prospective evaluation of a sample of a simple formula based on renal-function. J Clin Oncol. 1989;7(11):1748\u201356. https:\/\/doi.org\/10.1200\/jco.1989.7.11.1748.","journal-title":"J Clin Oncol"},{"issue":"Article 124211","key":"1002_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jchromb.2024.124211","volume":"1243","author":"J Ho","year":"2024","unstructured":"Ho J, Hartinger C, McKeage M, Han C. Improved method for quantification of intact oxaliplatin by ultra high performance liquid chromatography-inductively coupled plasma mass spectrometry: applications to clinical and speciation studies. J Chromatogr B. 2024;1243(Article 124211):10. https:\/\/doi.org\/10.1016\/j.jchromb.2024.124211.","journal-title":"J Chromatogr B"},{"issue":"6","key":"1002_CR20","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1039\/b716925f","volume":"23","author":"V Ip","year":"2008","unstructured":"Ip V, McKeage MJ, Thompson P, Damianovich D, Findlay M, Liu JJ. Platinum-specific detection and quantification of oxaliplatin and Pt(R, R-diaminocyclohexane)Cl-2 in the blood plasma of colorectal cancer patients. J Anal At Spectrom. 2008;23(6):881\u20134. https:\/\/doi.org\/10.1039\/b716925f.","journal-title":"J Anal At Spectrom"},{"issue":"4","key":"1002_CR21","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s002800050501","volume":"38","author":"JG Ma","year":"1996","unstructured":"Ma JG, Stoter G, Verweij J, Schellens JHM. Comparison of ethanol plasma protein precipitation with plasma ultrafiltration and trichloroacetic acid protein precipitation for the measurement of unbound platinum concentrations. Cancer Chemother Pharmacol. 1996;38(4):391\u20134. https:\/\/doi.org\/10.1007\/s002800050501.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"1002_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0731-7085(00)00377-0","volume":"24","author":"JG Morrison","year":"2000","unstructured":"Morrison JG, White P, McDougall S, Firth JW, Woolfrey SG, Graham MA, et\u00a0al. Validation of a highly sensitive ICP-MS method for the determination of platinum in biofluids: application to clinical pharmacokinetic studies with oxaliplatin. J Pharm Biomed Anal. 2000;24(1):1\u201310. https:\/\/doi.org\/10.1016\/S0731-7085(00)00377-0.","journal-title":"J Pharm Biomed Anal"},{"key":"1002_CR23","unstructured":"Anonymous. Bioanalytical Method Validation Guidance for Industry. U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM), 2018."},{"key":"1002_CR24","doi-asserted-by":"publisher","first-page":"100838","DOI":"10.1016\/j.eti.2020.100838","volume":"19","author":"Z Dong","year":"2020","unstructured":"Dong Z, Fan X, Fan W, Chang H, Xu Y, Li T, et\u00a0al. Pkweb: an online application for pharmacokinetic data analysis. Environ Technol Innov. 2020;19:100838. https:\/\/doi.org\/10.1016\/j.eti.2020.100838.","journal-title":"Environ Technol Innov"},{"issue":"11\u201312","key":"1002_CR25","first-page":"595","volume":"10","author":"FR Luo","year":"1998","unstructured":"Luo FR, Wyrick SD, Chaney SG. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncol Res. 1998;10(11\u201312):595\u2013603.","journal-title":"Oncol Res"},{"key":"1002_CR26","first-page":"333","volume-title":"Variability. Clinical pharmacokinetics and pharmacodynamics: concepts and applications","author":"M Rowland","year":"2011","unstructured":"Rowland M, Tozer TN. Variability. Clinical pharmacokinetics and pharmacodynamics: concepts and applications. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2011. p. 333\u201355.","edition":"4"},{"issue":"4","key":"1002_CR27","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/bf00684890","volume":"25","author":"JM Extra","year":"1990","unstructured":"Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase-I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 1990;25(4):299\u2013303. https:\/\/doi.org\/10.1007\/bf00684890.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"30","key":"1002_CR28","doi-asserted-by":"publisher","first-page":"3416","DOI":"10.1200\/jco.2014.58.8533","volume":"33","author":"DR Pachman","year":"2015","unstructured":"Pachman DR, Qin R, Seisler DK, Smith EML, Beutler AS, Ta LE, et\u00a0al. Clinical course of oxaliplatin-induced neuropathy: results from the randomized phase III trial N08CB (Alliance). J Clin Oncol. 2015;33(30):3416\u201322. https:\/\/doi.org\/10.1200\/jco.2014.58.8533.","journal-title":"J Clin Oncol"},{"issue":"24","key":"1002_CR29","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1200\/jco.2017.72.7578","volume":"35","author":"T Janowitz","year":"2017","unstructured":"Janowitz T, Williams EH, Marshall A, Ainsworth N, Thomas PB, Sammut SJ, et\u00a0al. New model for estimating glomerular filtration rate in patients with cancer. J Clin Oncol. 2017;35(24):2798\u2013805. https:\/\/doi.org\/10.1200\/jco.2017.72.7578.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1002_CR30","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1067\/mcp.2000.106827","volume":"67","author":"ADR Huitema","year":"2000","unstructured":"Huitema ADR, Mathot RAA, Tibben MM, Schellens JHM, Rodenhuis S, Beijnen JH. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods. Clin Pharmacol Ther. 2000;67(6):621\u201330. https:\/\/doi.org\/10.1067\/mcp.2000.106827.","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"1002_CR31","first-page":"4733","volume":"6","author":"M Ando","year":"2000","unstructured":"Ando M, Minami H, Ando Y, Saka H, Sakai S, Yamamoto M, et\u00a0al. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res. 2000;6(12):4733\u20138.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1002_CR32","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s00280-014-2667-6","volume":"75","author":"M Nikanjam","year":"2015","unstructured":"Nikanjam M, Stewart CF, Takimoto CH, Synold TW, Beaty O, Fouladi M, et\u00a0al. Population pharmacokinetic analysis of oxaliplatin in adults and children identifies important covariates for dosing. Cancer Chemother Pharmacol. 2015;75(3):495\u2013503. https:\/\/doi.org\/10.1007\/s00280-014-2667-6.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"1002_CR33","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/00001813-200311000-00007","volume":"14","author":"G Bastian","year":"2003","unstructured":"Bastian G, Barrail A, Urien S. Population pharmacokinetics of oxaliplatin in patients with metastatic cancer. Anticancer Drugs. 2003;14(10):817\u201324.","journal-title":"Anticancer Drugs"},{"issue":"2","key":"1002_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s00280-002-0550-3","volume":"51","author":"J-P Delord","year":"2003","unstructured":"Delord J-P, Umlil A, Guimbaud R, Gr\u00e9goire N, Lafont T, Canal P, et\u00a0al. Population pharmacokinetics of oxaliplatin. Cancer Chemother Pharmacol. 2003;51(2):127\u201331. https:\/\/doi.org\/10.1007\/s00280-002-0550-3.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"1002_CR35","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/01.ftd.0000191305.64775.04","volume":"28","author":"Y Kho","year":"2006","unstructured":"Kho Y, Jansman FGA, Prins NH, Neef C, Brouwers JRBJ. Population pharmacokinetics of oxaliplatin (85 mg\/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer. Ther Drug Monit. 2006;28(2):206\u201311. https:\/\/doi.org\/10.1097\/01.ftd.0000191305.64775.04.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"1002_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s00280-018-3722-5","volume":"83","author":"L Deyme","year":"2019","unstructured":"Deyme L, Barbolosi D, Gattacceca F. Population pharmacokinetics of FOLFIRINOX: a review of studies and parameters. Cancer Chemother Pharmacol. 2019;83(1):27\u201342. https:\/\/doi.org\/10.1007\/s00280-018-3722-5.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01002-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01002-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01002-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T17:25:28Z","timestamp":1781717128000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01002-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1002"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01002-4","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was supported by: Health Research Council of New Zealand (\n                      \n                      ) grants to MM (12\/254, 18\/323) and CH (12\/788, 18\/323) and Auckland Medical Research Foundation (\n                      \n                      ) grant to MM (1110014). JH was awarded a PhD scholarship from the University of Auckland. CH was awarded a Sir Owen Glenn Postdoctoral Clinical Research Fellowship. The University of Auckland supported the research through employment of MM and CH. The funders had no role in research design, data collection or analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This analysis used clinical pharmacokinetic datasets generated from previously published clinical studies [\n                      \n                      ,\n                      \n                      ]. The New Zealand clinical trial previously conducted by the authors was approved by the New Zealand Government Ministry of Health Northern Y Regional Ethics Committee (approval number NTY\/11\/01\/005) and conducted according to the ethical standards of the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Before any study procedures, participants gave written informed consent. Details of ethical approvals of the independent published clinical study can be found in its original report [\n                      \n                      ].","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data are fully available within the manuscript and supporting information.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}